Home
Live Updates
Supernus Pharmaceuticals : 2023 Annual Report : comparemela.com
Supernus Pharmaceuticals : 2023 Annual Report
Dear Supernus Stockholder,
We are very pleased with our performance in 2023 as we continued to successfully transition from our mature brands and set the stage to...
Related Keywords
Washington ,
United States ,
Rockville ,
Maryland ,
Delaware ,
Jacka Khattar ,
,
Stock Market ,
Shire Laboratories Inc ,
Takeda Pharmaceutical Company Ltd ,
Supernus Pharmaceuticals ,
Supernus Pharmaceuticals Inc ,
Nasdaq ,
Adamas Operations ,
Mdd Us Operations ,
Drug Administration ,
Securities Exchange ,
Exchange Commission ,
Shire Plc ,
Stock Exchange ,
Dear Supernus Stockholder ,
Novel Non Stimulant ,
Complete Response Letter ,
New Drug Application ,
Chief Executive Officer ,
West Avenue Rockville ,
Securities Exchange Act ,
Interactive Data File ,
Regulations T ,
Sarbanes Oxley Act ,
Proxy Statement ,
Annual Report ,
Year Ended December ,
For Registrant ,
Common Equity ,
Related Stockholder Matters ,
Equity Securities ,
Financial Condition ,
Qualitative Disclosures ,
Market Risk ,
Supplementary Data ,
Executive Officers ,
Corporate Governance ,
Certain Owners ,
Related Stockholder ,
Related Transactions ,
Director Independence ,
Accounting Fees ,
Financial Statement Schedules ,
Securities Act ,
New Drug Applications ,
Corporate Integrity Agreement ,
Shire Laboratories ,
Lennox Gastaut Syndrome ,
Itemi Business Intellectualproperty ,
Risk Factors Risksrelated ,
Standard Review ,
Investigational New Drug ,
Montgomery Asberg Depression Rating Scale ,
Total Score ,
Major Depressive Disorder ,
Hamilton Depression Rating ,
Orphan Drug ,
Dravet Syndrome ,
Markets ,
comparemela.com © 2020. All Rights Reserved.